Comparative Analysis of Quality Requirements for Medicines Based on Horse-Chestnut Seeds

Scientific relevance. When harmonising conditions for qualitative and quantitative analysis of bioactive compounds in herbal medicines, the Institute of Pharmacopoeia and Medicinal Product Standardisation has discovered that horse-chestnut products lack national quality standards.
Aim. This study aimed to review international quality standards in order to identify the most promising testing methods for the main groups of bioactive compounds in horse-chestnut seeds and draw upon these methods when drafting national pharmacopoeial monographs for horse-chestnut seed products.
Discussion. The authors compared the requirements established by leading world pharmacopoeias for the identification and assay of herbal drugs and herbal drug preparations derived from horse-chestnut seeds.
Conclusions. The study results show that, predominantly, identification tests are based on thin-layer chromatography, assays rely on spectrophotometry, and aescin is used as a pharmacopoeial reference standard. The authors drafted a pharmacopoeial monograph for the medicinal product Horse-Chestnut Seed Dry Extract + Thiamine Hydrochloride, Oral Solution, which requires using thin-layer chromatography and spectrophotometry for qualitative and quantitative testing.

1. Yablokov EG, Kirienko AI, Bogachev VYu. Chronic venous insufficiency. Moscow: Meditisina; 1999 (In Russ.).

2. Zolotukhin IA, Seliverstov EI, Shevtsov YuN, Avakiants IP, Nikishkov AI, Tatarintsev AM, Kirienko AI. Prevalence of chronic venous disease: results of population based epidemiological study. Phlebology. 2016;10(4):119–25 (In Russ.). https://doi.org/10.17116/flebo2016103119-125

3. Evans CJ, Fowkes FG, Ruckley CV, Lee AJ. Prevalence of varicose veins and chronic venous insufficiency in men and women in the general population: Edinburgh Vein Study. J Epidemiol Community Health. 1999;53(3):149–53. https://doi.org/10.1136/jech.53.3.149

4. Bielanski TE, Piotrowski ZH. Horse-chestnut seed extract for chronic venous insufficiency. J Fam Pract. 1999;48(3):171–2. PMID: 10086755

5. Kahn SR. Review: horse chestnut seed extract is effective for symptoms of chronic venous insufficiency. ACP J Club. 2006;145(1):20. PMID: 16813368

6. Persson IAL, Persson K. Horse chestnut (Aesculus hippocastanum L.). Recent Prog Med Plants. 2010;28:159–71.

7. Evdokimova OV, Beketova AV, Lyakina MN. Determination of anthracene derivatives in herbal medicines. Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2021;11(2):104–14 (In Russ.). https://doi.org/10.30895/1991-2919-2021-11-2-104-114

8. Zhang Z, Li S, Yuan X. An overview of Genus Aesculus L.: ethnobotany, phytochemistry, and pharmacological activities. Pharm Crops. 2010;1(1):24–51. https://doi.org/10.2174/2210290601001010024

9. Wulff G, Tschesche R. Uber triterpene-XXVI. Uber die struktur der rosskastaniensaponine (aescin) und die aglykone verwandter glykoside. Tetrahedron. 1969;25:415–36.

10. Konoshima T, Lee KH. Antitumor agents, 82. Cytotoxic sapogenols from Aesculus hippocastanum. J Nat Prod. 1986;49(4):650–6. https://doi.org/10.1021/np50046a015

11. Kuhn R, Low I. Uber die protoascigenin aus ascin. Tetrahedron. 1966;22:1899–906.

12. Yoshikawa M, Harada E, Murakami T, Matsuda H, Wariishi N, Yamahara J, Murakami N, Kitagawa I. Escins Ia, Ib, IIa, IIb, and IIIa, bioactive triterpene oligoglycosides from the seeds of Aesculus hippocastanum L.: their inhibitory effects on ethanol absorption and hypoglycemic activity on glucose tolerance test. Chem Pharm Bull (Tokyo). 1994;42(6):1357–9. https://doi.org/10.1248/cpb.42.1357

13. Yoshikawa M, Murakami T, Matsuda H, Yamahara J, Murakami N, Kitagawa I. Bioactive saponins and glycosides. III. Horse chestnut. (1): the structures, inhibitory effects on ethanol absorption, and hypoglycemic activity of escins Ia, Ib, IIa, IIb, and IIIa from the seeds of Aesculus hippocastanum L. Chem Pharm Bull (Tokyo). 1996;44(8):1454–64. https://doi.org/10.1248/cpb.44.1454

14. Yoshikawa M, Murakami T, Yamahara J, Matsuda H. Bioactive saponins and glycosides. XII. Horse chesnut. (2): Structures of escins IIIb, IV, V, and VI and Isoescins Ia, Ib, and V, acylated polyhydroxyoleanene triterpene oligoglycosides, from the seeds of horse chestnut tree (Aesculus hippocastanum L., Hippocastanaceae). Chem Pharm Bull (Tokyo). 1998;46(11):1764–9. https://doi.org/10.1248/cpb.46.1764

15. Pietta P, Mauri P, Maffei Faccino R, Carini M. High-performance liquid chromatographic analysis of β-escin. J Chromatogr A. 1989;478:259–63. https://doi.org/10.1016/0021-9673(89)90026-5

16. Facino RM, Carini M, Moneti G, Arlandini E, Pietta P, Mauri P. Mass spectrometric characterization of horse chestnut saponins (escin). Org Mass Spectrom. 1991;26:989.

17. Комиссаренко НФ, Деркач АИ, Комиссаренко АН, Черменева ГВ, Спиридонов ВН. Кумарины Aesculus hippocastanum L. Растительные ресурсы. 1994;30(3):53–9. Komissarenko NF, Derkach AI, Komissarenko AN, Cheremnyova GV, Spiridonov VN. Coumarins of Aesculus hippocastanum L. Rastitel’nye Resursy. 1994;30(3):53–9 (in Russ.).

18. Srijayanta S, Raman A, Goodwin BL. A comparative study of the constituents of Aesculus hippocastanum and Aesculus indica. J Med Food. 1999;2(2):45–50. https://doi.org/10.1089/jmf.1999.2.45

19. Azimova LB, Filatova AV, Turaev AS, Dzhurbaev DT. Isolation and study of the polysaccharide complex isolated from Aesculus hippocastanum L. Chemistry of Plant Raw Material. 2021;(3):115–22 (In Russ.). https://doi.org/10.14258/jcprm.2021039173

20. Sirtori CR. Aescin: pharmacology, pharmacokinetics and therapeutic profile. Pharmacol Res. 2001;44(3):183–93. https://doi.org/10.1006/phrs.2001.0847

21. Kirienko AI, Grigoryan RA, Zolotukhin IA. Current principles in the treatment of chronic venous insufficiency. Consilium Medicum. 2003;5(6):361–6 (In Russ.). EDN: UDGSMH

22. Muraki K, Imaizumi Y, Watanabe M. Ca-dependent K channels in smooth muscle cells permeabilized by h-escin recorded using the cellattached patch-clamp technique. Pflugers Arch. 1992;420(5–6):461–9. https://doi.org/10.1007/bf00374620

23. Pearson PJ, Vanhoutte PM. Vasodilator and vasoconstrictor substances produced by the endothelium. Rev Physiol Biochem Pharmacol. 1993;122:1–67. https://doi.org/10.1007/bfb0035273

24. Berti F, Omini C, Longiave D. The mode of action of aescin and the release of prostaglandins. Prostaglandins. 1977;14(2):241–9. https://doi.org/10.1016/0090-6980(77)90169-1

25. Guillaume M, Padioleau V. Veinotonic effect, vascular protection, antiinflammatory and free radical scavenging properties of horse chestnut extract. Arzneimittelforschung. 1994;44(1):25–35. PMID: 8135874

26. Panigati D. Farmacologia dell’escina, saponina dell’Aesculus hippocastanum L. Parte II. Farmacologia dell’escina. Capitolo I. Boll Chim Farm. 1992;131:242–6.

27. Matsuda H, Li Y, Yoshikawa M. Possible involvement of 5-HT and 5-HT2 receptors in acceleration of gastrointestinal transit by escin Ib in mice. Life Sci. 2000;66(23):2233–8. https://doi.org/10.1016/s0024-3205(00)00551-8

28. Facino RM, Carini M, Stefani R, Aldini G, Saibene L. Antielastase and anti-hyaluronidase activities of saponins and sapogenins from Hedera helix, Aesculus hippocastanum, and Ruscus aculeatus: factors contributing to their efficacy in the treatment of venous insufficiency. Arch Pharm (Weinheim).1995;328(10):20–4. https://doi.org/10.1002/ardp.19953281006

29. Matsuda H, Li Y, Murakami T, Ninomiya K, Yamahara J, Yoshikawa M. Effects of escins Ia, Ib, IIa, and IIb from horse chestnut, the seeds of Aesculus hippocastanum L., on acute inflammation in animals. Biol Pharm Bull. 1997;20(10):1092–5. https://doi.org/10.1248/bpb.20.1092

30. Felixsson E, Persson IA, Eriksson AC, Persson K. Horse chestnut extract contracts bovine vessels and affects human platelet aggregation through 5-HT(2A) receptors: an in vitro study. Phytother Res. 2010;24(9):1297–301. https://doi.org/10.1002/ptr.3103

31. Küçükkurt I, Ince S, Keleş H, Akkol EK, Avci G, Yeşilada E, Bacak E. Beneficial effects of Aesculus hippocastanum L. seed extract on the body’s own antioxidant defense system on subacute administration. J Ethnopharmacol. 2010;129(1):18–22. https://doi.org/10.1016/j.jep.2010.02.017

32. Patlolla JM, Raju J, Swamy MV, Rao CV. Beta-escin inhibits colonic aberrant crypt foci formation in rats and regulates the cell cycle growth by inducing p21(waf1/cip1) in colon cancer cells. Mol Cancer Ther. 2006;5(6):1459–66. https://doi.org/10.1158/1535-7163.mct-05-0495